ID: ALA327721

Max Phase: Preclinical

Molecular Formula: C25H28N4S

Molecular Weight: 416.59

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1CCN(CCCn2cc(-c3cncc(-c4ccsc4)c3)c3ccccc32)CC1

Standard InChI:  InChI=1S/C25H28N4S/c1-27-10-12-28(13-11-27)8-4-9-29-18-24(23-5-2-3-6-25(23)29)22-15-21(16-26-17-22)20-7-14-30-19-20/h2-3,5-7,14-19H,4,8-13H2,1H3

Standard InChI Key:  FYOYABXHBTZQMB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 416.59

Molecular Weight (Monoisotopic): 416.2035

AlogP: 5.07

#Rotatable Bonds: 6

Polar Surface Area: 24.30

Molecular Species: BASE

HBA: 5

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.71

CX LogP: 4.08

CX LogD: 2.75

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.44

Np Likeness Score: -1.82

References

1. Fraley ME, Arrington KL, Hambaugh SR, Hoffman WF, Cunningham AM, Young MB, Hungate RW, Tebben AJ, Rutledge RZ, Kendall RL, Huckle WR, McFall RC, Coll KE, Thomas KA..  (2003)  Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.,  13  (18): [PMID:12941314] [10.1016/s0960-894x(03)00627-9]

2. Jacquemard U, Dias N, Lansiaux A, Bailly C, Logé C, Robert JM, Lozach O, Meijer L, Mérour JY, Routier S..  (2008)  Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents.,  16  (9): [PMID:18439832] [10.1016/j.bmc.2008.03.034]

3. Mondal D, Amin SA, Moinul M, Das K, Jha T, Gayen S..  (2022)  How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors.,  53  [PMID:34864496] [10.1016/j.bmc.2021.116534]

Source

Source(1):

• Scientific Literature